Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Viking Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VKTX
Nasdaq
2830
www.vikingtherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Viking Therapeutics, Inc.
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
- Aug 28th, 2026 9:30 am
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
- Aug 27th, 2026 9:05 am
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
- Aug 19th, 2026 9:46 am
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
- Aug 17th, 2026 9:09 am
2 GLP-1 Stocks That Could Double Your Money by 2031
- Aug 16th, 2026 2:20 pm
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
- Aug 13th, 2026 7:42 am
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
- Aug 12th, 2026 9:10 am
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
- Aug 8th, 2026 1:50 pm
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
- Aug 6th, 2026 8:41 am
Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?
- Aug 4th, 2026 4:14 am
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why
- Aug 4th, 2026 12:32 am
Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says
- Aug 3rd, 2026 10:44 am
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
- Aug 3rd, 2026 9:43 am
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
- Jul 30th, 2026 4:50 pm
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
- Jul 30th, 2026 11:00 am
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
- Jul 30th, 2026 10:35 am
Scroll